Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
Cole
Jason H
JH
Division of Cardiology, Emory University School of Medicine, Atlanta, Ga 30306, USA.
Weintraub
William S
WS
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy / Q000191:economics / Q000401:mortality / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D012449:Safety; D015607:Stents / Q000191:economics
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab